This content is from: Features
Poison pill ruling may weaken French targets
Aventis and Sanofi-Synthelabo are set to merge after a tense three-month standoff. But at what price? Megan Murphy looks at whether a regulatory decision could leave French companies more vulnerable to takeover
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an IFLR subscriber? Login here